Fast and effective wound healing

Negative Pressure Wound Therapy

What are your wound management challenges?

Healthcare professionals and KCI are always looking for ways to heal
wounds faster and more effectively, to improve the quality of life of
patients and to reduce overall therapy costs.

Efficacy?

Healing times?

Patient quality
of life?

Costs?


“ The challenges of effective

wound management are


becoming increasingly complex.
“
C J Moffatt, European Wound Management Association (EWMA). Position Document:
Topical negative pressure in wound management. London: MEP Ltd, 2007.
Is there a better approach
to wound healing?

3
A better approach to wound healing

The scientifically and clinically proven

mechanisms of action behind V.A.C.® Therapy
promote fast and effective wound healing.1–5

Mechanisms
of action
• Moist wound
healing
• Granulation
tissue formation
• Oedema reduction
• Enhanced
perfusion
• Removes wound
exudate containing
molecules that can
inhibit wound
healing
• Stimulates cell
proliferation

Case Report: Trauma wound6

At presentation Day 0 Day 2 Conclusion
A 91-year-old
female with a
haematoma to
the lower leg
secondary to a fall.
Wound after removal of The undermined area After 48 hours the After 8 days inpatient and
hard necrotic tissue. was filled with V.A.C.® undermined area had 14 days care in the home
GranuFoam® Dressing. decreased in size. undermining was eliminated
and granulation tissue was
level with wound margin.

The V.A.C.® Therapy advantage
Macrostrain – Tissue level activity
V.A.C.® GranuFoam®
Dressing Gauze dressing Advantages
V.A.C.® GranuFoam® Dressings provide direct,
complete contact with the wound bed. They
contract under negative pressure drawing the
wound edges together and reducing wound
volume. These pulling forces also remove
exudate and infectious materials.
Microstrain – Cellular level activity
GranuFoam® Gauze Fibres V.A.C.® GranuFoam® Dressings
induce microdeformation of tissue.5

Tissue Interaction Tissue Interaction

V.A.C.® GranuFoam® Dressings demonstrate

3x more fibroblast migration when compared
with gauze.5

V.A.C.® GranuFoam® Dressings demonstrate

increased proliferation. Cell death is 2.4 x greater
with gauze than with V.A.C.® GranuFoam®
Dressing.5

V.A.C.® Therapy
efficiently
manages large
volumes of
exudate and
accelerates the
healing time of
complex wounds.§


V.A.C.® Therapy: faster 2 and more effective4 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5

Reduction in ulcer area at Day 28 (cm2)

V.A.C.® Therapy prepares the wound bed

over twice as fast 2

Time to wound
bed preparation
was cut from 17
to 7 days with
V.A.C.® Therapy.2
Faster wound bed preparation

17 days
CONTROL
in V.A.C.® Therapy group

[10-24]

7 days
[5.7-8.3] V.A.C® THERAPY p = 0.005

0 2 4 6 8 10 12 14 16 18 20

Duration needed for wound bed preparation (days)

A Randomised Controlled Trial covering 60 chronic leg ulcer patients

compared against advanced moist wound dressings.
Graph adapted from: Vuerstaek et al Journal of Vascular Surgery. 2006.2

Case Report: Chronic wound6

Day minus 30 Day 0 Day 11 Day 54
A diabetic
female following
amputation of
the left second
digit and
metatarsal head.
Amputation of head of Following complications, With no improvement for At 54 days V.A.C.® Therapy
second metatarsal. and removal of 1 month, V.A.C.® Therapy was discontinued as the
non-viable tissue. was applied and reduced wound bed showed 100%
slough coverage to 40% granulation tissue coverage.
of the wound surface.

 V.A.C.® Therapy is 71% more effective
in reducing wound area4

Wound area
reduced by
4.32 cm2 under
V.A.C.® Therapy
2.53 cm2 CONTROL p < 0.021 compared to only
2.53 cm2 under
Diabetic foot ulcers*

control.4

4.32 cm2 V.A.C® THERAPY

*Average baseline wound area for

patients treated with V.A.C.® Therapy
is 13.5 cm2 and for patients treated
with AMWT 11.0 cm2.
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5

Reduction in ulcer area at Day 28 (cm2)

A Randomised Control Trial of 342 patients compared against

predominantly hydrogels and alginates across 37 centres.
Graph adapted from: Blume et al Diabetes Care. 2008.4

The healed foot is

Faster wound bed preparation

17 days
CONTROL
functional and can
in V.A.C.® Therapy group

[10-24]
be accommodated
within semi-
bespoke footwear,
the plantar tissues
show no significant
scarring or areas of
7 days
[5.7-8.3] V.A.C® THERAPY p = 0.005 high pressure.§


Impacting positively on healthcare providers and patients

V.A.C.® Therapy cuts treatment

costs by a third7

Treatment
costs cut by
$12,852 using
V.A.C.® Therapy.7
$38.806 CONTROL
to achieve 100% healing
Average total cost

$25.954 V.A.C® THERAPY

0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000

USD ($)

A Randomised Controlled Trial of 162 patients using V.A.C.® Therapy treating

diabetic foot wounds compared against advanced moist wound care.
Graph adapted from: Apelqvist et al The American Journal of Surgery. 2008.7

Case Report: Acute wound6

Day 0 Day 0 Day 24 Day 60
A 55-year-old
woman with
necrotising
fasciitis requiring
radical surgical
debridement.
Initiation of V.A.C.® Therapy was The patient was V.A.C.® Therapy was
V.A.C.® Therapy applied over exposed discharged home on the discontinued. 98% of
after radical surgical bowel. V.A.C.® Freedom unit skin graft was taken
debridement of after a 72% reduction successfully.
abdominal wound. in wound size.

 V.A.C.® Therapy significantly improves
patient quality of life8

Overall quality of life

Physical **p<0.01 ***p<0.001
complaints *** improved with
V.A.C.® Therapy.8
Everyday life
complaints ***

Social life
complaints ***

Psychological
complaints ***

Therapy
burden ***

Complaints with
satisfaction **

Overall PRIOR TO V.A.C® THERAPY

complaints ***
AFTER V.A.C® THERAPY

1 2 3 4 5
1 = no impact 5 = high impact

A questionnaire comparison study in which 98 centres compared data

before and after V.A.C.® Therapy.
Graph adapted from: Augustin et al MMW-Fortschritte der Medizin
Originalien, 2006 8

V.A.C.® Therapy was

used to promote
rapid growth
of granulation
tissue in a patient
with a number
of comorbidities
who was at risk of
delayed healing.§


You care for your patient: we’ll give you the support you need

KCI – your wound care partner

• Introductory training and ongoing education.
• 24-hour customer service to address real-time requirements.
• Continued research and development investment.
• Support from our healthcare economic team with any budget concerns.
• More than 137,000 caregivers trained world wide in 2007 alone.

10
V.A.C.® Therapy is the validated NPWT
• Over 16 Randomised Controlled Trials.
• Over 450 peer-reviewed articles including health economic evidence.
• M
 ore than 3 million patients treated to date – with 30,000 patients assisted
world-wide every single day.
• Established mechanisms of action at cellular and tissue levels.

To date over

16
Randomised Control Trials

over

450
peer-reviewed articles

over...

3 million
patients treated with V.A.C.® Therapy

11
V.A.C.® Therapy. Faster, more effective and clinically
proven wound healing.

Prepares the wound 71% more effective in

bed over twice as fast. reducing wound area.

Cuts treatment Significantly improves

costs by a third. quality of life.

Comprehensive customer, Over 16 RCT’s and 450 peer-

technical training and reviewed articles to date.
support.

Can you think of a patient who could benefit from

V.A.C.® Therapy today?

Contact KCI today – 0800 980 8880 – www.kci-medical.com

References 1. Hunter JE, Teot L, Horch R, Banwell PE. Evidence based medicine: vacuum-assisted closure in wound care management. International Wound Journal 2007, 4:256-69.
2. Vuerstaek JD, Jeroen DD, Vainas T, Wuite J, Nelemans P, Neumann MHA, Veraart JCJM. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-
assisted closure (V.A.C.®) with modern wound dressings. Journal of Vascular Surgery 2006, 44(5):1029-37. 3. Armstrong DG & Lavery LA. Negative Pressure Wound Therapy after partial
Diabetic Foot Amputation: a multicentre, randomised controlled trial. Lancet 2005, 366:1704-10. 4. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of Negative Pressure Wound Therapy
using Vacuum-assisted Closure with Advanced Moist Wound Therapy in the Treatment of Diabetic Foot Ulcers. Diabetes Care 2008, 31:631-36. 5. McNulty AK, Schmidt BS, Feeley T, Kieswetter K. Effects of
negative pressure wound therapy on fibroblast viability, chemotactic signaling, and proliferation in a provisional wound (fibrin) matrix. Wound Repair and Regeneration 2007, 15:838-46. 6. Gray,
D. Russell, F. Timmons, J: Editors. VAC Therapy: An introduction and practical guide. Wounds UK, 2009. 7. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJM. Resource utilization and
economic cost of care based on a randomized trial of Vacuum-assisted Closure therapy in the treatment of diabetic foot wounds. The American Journal of Surgery 2008, 195(6):782-88.
8. Augustin M, Zschocke I. Nutzenbewertung der Ambulanten und Stationaeren V.A.C.® Therapie aus Patientensicht. MMW-Fortschritte der Medizin Originalien 2006, 1(148):S25–32. § Patient
photographs are posed by models.

United Kingdom kci international GLOBAL HEAD OFFICE © 2009 KCI Licensing, Inc. All Rights Reserved. All trademarks designated
KCI Medical Ltd head office KCI International herein are property of KCI Licensing, Inc, its affiliates and licensors. Those
KCI House KCI Europe Holding B.V. 8023 Vantage Drive KCI trademarks designated with the “®” symbol are registered and those
Langford Business Park Parktoren, 6th Floor San Antonio designated with “TM” are considered to be proprietary trademarks or are
Langford Locks Van Heuven Goedhartlaan 11 TX 78230 pending trademark applications in at least one country where this product/
Kidlington OX5 1GF PO Box 129 U.S.A. work is commercialized. Most KCI products referred to herein are subject to
United Kingdom 1180 AC Amstelveen T(free) 1 800 531 5396, patents or patent applications.
24h Customer Support The Netherlands extension 6335
KCI Advantage Centre Tel +31 (0) 20 426 0000 Tel +1 210 255 6335
Tel +44 (0) 800 980 8880 Fax +31 (0) 20 426 0099 Fax +1 210 255 6991
Fax +44 (0)1865 840 626 www.kci-medical.com www.kci-medical.com
www.kci-medical.com

KCI Product code KCII 1081-01-09-En